U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H24NO4.CH3O4S
Molecular Weight 429.485
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of N-METHYLSCOPOLAMINE METHYLSULFATE

SMILES

COS([O-])(=O)=O.C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]3O[C@@H]23)OC(=O)[C@H](CO)C4=CC=CC=C4

InChI

InChIKey=KHMGIQHRSVLFQG-RAFJPFSSSA-M
InChI=1S/C18H24NO4.CH4O4S/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11;1-5-6(2,3)4/h3-7,12-17,20H,8-10H2,1-2H3;1H3,(H,2,3,4)/q+1;/p-1/t12-,13-,14-,15+,16-,17+;/m1./s1

HIDE SMILES / InChI

Molecular Formula C18H24NO4
Molecular Weight 318.3875
Charge 1
Count
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 6 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula CH3O4S
Molecular Weight 111.097
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Methscopolamine bromide is an anticholinergic agent used along with other medications to treat peptic ulcers by reducing stomach acid secretion. Methscopolamine is also commonly used as a drying agent, to dry up post-nasal drip, in cold, irritable bowel syndrome and allergy medications. Methscopolamine binds to M1-M5 isoforms of muscarinic receptors.

CNS Activity

Curator's Comment: Methscopolamine bromide has limited ability to cross the blood-brain-barrier

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PAMINE

Approved Use

Methscopolamine bromide is an anticholinergic agent which possesses most of the pharmacological actions of that drug class. These include reduction in volume and total acid content of gastric secretion, inhibition of gastrointestinal motility, inhibition of salivary excretion, dilation of the pupil and inhibition of accommodation with resulting blurring of vision. Large doses may result in tachycardia.

Launch Date

1953
Palliative
DALLERGY

Approved Use

This product provides relief of the symptoms resulting from irritation of sinus, nasal, and upper respiratory tract tissue. Phenylephrine exerts a vasoconstrictive and decongestive action while chlorpheniramine maleate decreases the symptoms of watering eyes, post nasal drip, and sneezing. Methscopolamine nitrate further augments the antisecretory activity of this product.
Palliative
DALLERGY

Approved Use

This product provides relief of the symptoms resulting from irritation of sinus, nasal, and upper respiratory tract tissue. Phenylephrine exerts a vasoconstrictive and decongestive action while chlorpheniramine maleate decreases the symptoms of watering eyes, post nasal drip, and sneezing. Methscopolamine nitrate further augments the antisecretory activity of this product.
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway.
2010-10
Attenuation of cocaine's reinforcing and discriminative stimulus effects via muscarinic M1 acetylcholine receptor stimulation.
2010-03
Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors.
2006-08
Allosteric interactions with muscarinic acetylcholine receptors: complex role of the conserved tryptophan M2422Trp in a critical cluster of amino acids for baseline affinity, subtype selectivity, and cooperativity.
2006-07
Identification of various allosteric interaction sites on M1 muscarinic receptor using 125I-Met35-oxidized muscarinic toxin 7.
2006-05
Allosteric site in M2 acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist.
2006-01
Modifications in muscarinic, dopaminergic and serotonergic receptors concentrations in the hippocampus and striatum of epileptic rats.
2005-12-05
Critical amino acid residues of the common allosteric site on the M2 muscarinic acetylcholine receptor: more similarities than differences between the structurally divergent agents gallamine and bis(ammonio)alkane-type hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide.
2005-09
Asparagine, valine, and threonine in the third extracellular loop of muscarinic receptor have essential roles in the positive cooperativity of strychnine-like allosteric modulators.
2005-05
Pilocarpine-induced seizures in adult rats: monoamine content and muscarinic and dopaminergic receptor changes in the striatum.
2003-10
Bisquaternary dimers of strychnine and brucine. A new class of potent enhancers of antagonist binding to muscarinic M2 receptors.
2003-06-12
Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors.
2002-12
Zebrafish M2 muscarinic acetylcholine receptor: cloning, pharmacological characterization, expression patterns and roles in embryonic bradycardia.
2002-11
Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site.
2000-07
A snake venom inhibitor to muscarinic acetylcholine receptor (mAChR): isolation and interaction with cloned human mAChR.
2000-05-15
Allosteric effects of four stereoisomers of a fused indole ring system with 3H-N-methylscopolamine and acetylcholine at M1-M4 muscarinic receptors.
1999
Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells.
1998-11
Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies.
1998-03
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
1997-07
Central cholinergic mechanisms in L-DOPA induced hyperactive urinary bladder of the rat.
1982
Effect of cholingeric drugs on methadone-induced catalepsy and stereotypies in rats treated chronically with methadone.
1976-10
Patents

Patents

Sample Use Guides

The average dosage of Methscopolamine Bromide Tablets USP is 2.5 mg one-half hour before meals and 2.5 to 5 mg at bedtime. A starting dose of 12.5 mg daily will be clinically effective in most patients without the production of appreciable side effects.
Route of Administration: Oral
In Vitro Use Guide
In the standard assay, mAChR subtypes (20-30 fmol/tube) in particulate fractions of Sf9 cells were incubated with 4 to 4.2 nM [3H]NMS (methscopolamine) and different concentrations of muscarinic ligands in 20 mM K-phosphate buffer (pH 7). Bound [3H]NMS trapped on the filter was counted with a liquid scintillation counter.
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:23:27 GMT 2025
Edited
by admin
on Mon Mar 31 21:23:27 GMT 2025
Record UNII
R044N53C06
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
N-METHYLSCOPOLAMINE METHYLSULFATE
JAN  
Common Name English
HYOSCINE METILSULFATE
WHO-DD  
Preferred Name English
ULIX
Brand Name English
N-METHYLSCOPOLAMINE METHYL SULFATE
Common Name English
N-Methylscopolamine methylsulfate [WHO-DD]
Common Name English
METHYLSCOPOLAMMONIUM METHYLSULFATE
Common Name English
DAIPIN
Brand Name English
N-METHYLSCOPOLAMINE METHOSULFATE
Common Name English
N-METHYLSCOPOLAMINE METHYLSULFATE [JAN]
Common Name English
N-METHYLSCOPOLAMMONIUM METHOSULFATE
Common Name English
DD-234
Code English
SANDRIX
Brand Name English
ESPASMO GASIUM
Brand Name English
N-METHYLSCOPOLAMMONIUM METHYL SULFATE
Common Name English
METHSCOPOLAMINE METHYLSULFATE
Common Name English
N-METHYLHYOSCINE METHYL SULFATE
Common Name English
METHYLSCOPOLAMINE METHYL SULFATE
Common Name English
3-OXA-9-AZONIATRICYCLO(3.3.1.02,4)NONANE, 7-(3-HYDROXY-1-OXO-2-PHENYLPROPOXY)-9,9-DIMETHYL-, (7(S)-(1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.))-, METHYL SULFATE (SALT)
Common Name English
TROPIC ACID, (-)-, ESTER WITH 6.BETA.,7.BETA.-EPOXY-3.ALPHA.-HYDROXY-8-METHYL-1.ALPHA.H,5.ALPHA.H-TROPANIUM METHYL SULFATE
Common Name English
1.ALPHA.H,5.ALPHA.H-TROPANIUM, 6.BETA.,7.BETA.-EPOXY-3.ALPHA.-HYDROXY-8-METHYL-, METHYL SULFATE, (-)-TROPATE
Common Name English
Code System Code Type Description
EVMPD
SUB14159MIG
Created by admin on Mon Mar 31 21:23:27 GMT 2025 , Edited by admin on Mon Mar 31 21:23:27 GMT 2025
PRIMARY
SMS_ID
100000077608
Created by admin on Mon Mar 31 21:23:27 GMT 2025 , Edited by admin on Mon Mar 31 21:23:27 GMT 2025
PRIMARY
FDA UNII
R044N53C06
Created by admin on Mon Mar 31 21:23:27 GMT 2025 , Edited by admin on Mon Mar 31 21:23:27 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201268
Created by admin on Mon Mar 31 21:23:27 GMT 2025 , Edited by admin on Mon Mar 31 21:23:27 GMT 2025
PRIMARY
EPA CompTox
DTXSID50939371
Created by admin on Mon Mar 31 21:23:27 GMT 2025 , Edited by admin on Mon Mar 31 21:23:27 GMT 2025
PRIMARY
EVMPD
SUB36127
Created by admin on Mon Mar 31 21:23:27 GMT 2025 , Edited by admin on Mon Mar 31 21:23:27 GMT 2025
ALTERNATIVE
CAS
18067-13-5
Created by admin on Mon Mar 31 21:23:27 GMT 2025 , Edited by admin on Mon Mar 31 21:23:27 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY